Cargando…

Muscular Dystrophy Meets the Gene Chip: New Insights into Disease Pathogenesis

Detalles Bibliográficos
Autor principal:	Chamberlain, Jeffrey S.
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2000
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2190594/ https://www.ncbi.nlm.nih.gov/pubmed/11121429

Ejemplares similares

Tissue Rings PLOD Out a Second Hit in Becker Muscular Dystrophy
por: Lee, Benjamin W., et al.
Publicado: (2023)

The Immune System in Duchenne Muscular Dystrophy Pathogenesis
por: Tripodi, Luana, et al.
Publicado: (2021)

Muscle-on-a-chip devices: a new era for in vitro modelling of muscular dystrophies
por: Fernández-Costa, Juan M., et al.
Publicado: (2023)

Cas9 immunity creates challenges for CRISPR gene editing therapies
por: Crudele, Julie M., et al.
Publicado: (2018)

A Role for Caveolin-3 in the Pathogenesis of Muscular Dystrophies
por: Pradhan, Bhola Shankar, et al.
Publicado: (2020)

DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2020)

Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials
por: Wang, Zejing, et al.
Publicado: (2011)

Editorial for the Genetics of Muscular Dystrophies from the Pathogenesis to Gene Therapy Special Issue
por: Politano, Luisa, et al.
Publicado: (2023)

Animal Models for Muscular Dystrophy Show Different Patterns of Sarcolemmal Disruption
por: Straub, Volker, et al.
Publicado: (1997)

Multi-Parametric MRI at 14T for Muscular Dystrophy Mice Treated with AAV Vector-Mediated Gene Therapy
por: Park, Joshua, et al.
Publicado: (2015)

Zebrafish orthologs of human muscular dystrophy genes
por: Steffen, Leta S, et al.
Publicado: (2007)

The metabolomic plasma profile of patients with Duchenne muscular dystrophy: providing new evidence for its pathogenesis
por: Xu, Huayan, et al.
Publicado: (2023)

Advances in gene therapy for muscular dystrophies
por: Abdul-Razak, Hayder, et al.
Publicado: (2016)

The Duchenne muscular dystrophy gene and cancer
por: Jones, Leanne, et al.
Publicado: (2020)

Gene Therapy for Duchenne Muscular Dystrophy
por: Elangkovan, Nertiyan, et al.
Publicado: (2021)

GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?
por: Favalli, Ennio Giulio, et al.
Publicado: (2020)

Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy
por: Larkindale, Jane, et al.
Publicado: (2017)

Identifying the hub genes for Duchenne muscular dystrophy and Becker muscular dystrophy by weighted correlation network analysis
por: Wang, Junjie, et al.
Publicado: (2021)

Transcriptome profiling identifies regulators of pathogenesis in collagen VI related muscular dystrophy
por: Butterfield, Russell J., et al.
Publicado: (2017)

The Role of P2X7 Purinoceptors in the Pathogenesis and Treatment of Muscular Dystrophies
por: Zabłocki, Krzysztof, et al.
Publicado: (2023)

Distribution of myosin heavy chain isoforms in muscular dystrophy: insights into disease pathology
por: Beedle, Aaron M
Publicado: (2016)

Cardiovascular Disease in Duchenne Muscular Dystrophy: Overview and Insight Into Novel Therapeutic Targets
por: Schultz, Taylor I., et al.
Publicado: (2022)

Muscular Dystrophy: Disease Mechanisms and Therapies
por: Pandey, Sachchida Nand, et al.
Publicado: (2015)

Meetings managed
por: Smith, Tim
Publicado: (2022)

Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy
por: Bengtsson, Niclas E., et al.
Publicado: (2017)

Tissue transglutaminase in the pathogenesis of heart failure
por: Shinde, Arti V., et al.
Publicado: (2017)

Ophthalmic complications of dengue: pathogenesis and prevention
por: Uma, Alagappan, et al.
Publicado: (2013)

Saying NO to muscular dystrophy
por: Dove, Alan W.
Publicado: (2001)

Fatigue in muscular dystrophies
por: Angelini, Corrado, et al.
Publicado: (2012)

Gene Therapy Rescues Cardiac Dysfunction in Duchenne Muscular Dystrophy Mice by Elevating Cardiomyocyte Deoxy-Adenosine Triphosphate
por: Kolwicz, Stephen C., et al.
Publicado: (2019)

Gene Therapy for Muscular Dystrophies: Progress and Challenges
por: Park, Kyung Seok, et al.
Publicado: (2010)

Gene Editing to Tackle Facioscapulohumeral Muscular Dystrophy
por: Mariot, Virginie, et al.
Publicado: (2022)

The Rad52 SSAP superfamily and new insight into homologous recombination
por: Al-Fatlawi, Ali, et al.
Publicado: (2023)

Cardiac Dysrhythmias, Cardiomyopathy and Muscular Dystrophy in Patients with Emery-Dreifuss Muscular Dystrophy and Limb-Girdle Muscular Dystrophy Type 1B
por: Hong, Jong-Seo, et al.
Publicado: (2005)

Corrigendum: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy
por: Bengtsson, Niclas E., et al.
Publicado: (2017)

Tryptophan: ‘essential’ for the pathogenesis of irritable bowel syndrome?
por: Berstad, Arnold, et al.
Publicado: (2014)

An ex vivo Gene Therapy Approach to Treat Muscular Dystrophy Using inducible Pluripotent Stem Cells
por: Filareto, Antonio, et al.
Publicado: (2013)

Membrane-myofibril cross-talk in myofibrillogenesis and in muscular dystrophy pathogenesis: lessons from the zebrafish
por: Raeker, Maide Ö., et al.
Publicado: (2014)

Defective autophagy and increased apoptosis contribute toward the pathogenesis of FKRP-associated muscular dystrophies
por: Ortiz-Cordero, Carolina, et al.
Publicado: (2021)

Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model
por: Howard, Zachary M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3nevg6ubpsbap4p2n7gpm2op7h